$ALT
Altimmune Inc Stock $alt

$alt Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000114420413043745 Filed on August 08, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$31.00	$1.656K	$6.320M
YoY Change	-100.0%	-99.97%	-1.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.090M	$2.330M	$2.780M
YoY Change	24.7%	-16.19%	-18.48%
% of Gross Profit
Research & Development	$2.556M	$3.403M	$4.919M
YoY Change	-50.25%	-30.82%	-17.8%
% of Gross Profit
Depreciation & Amortization	$44.59K	$41.85K	$70.00K
YoY Change	-38.45%	-40.21%	-36.36%
% of Gross Profit
Operating Expenses	$6.687M	$5.777M	$7.775M
YoY Change	-21.2%	-25.7%	-18.24%
Operating Profit	-$3.199M	-$1.482M	-$1.458M
YoY Change	78.69%	1.61%	-52.68%
Interest Expense	$89.82K	$100.0K	$111.4K
YoY Change	-20.18%	-10.17%	633.89%
% of Operating Profit
Other Income/Expense, Net	-$717.9K	$256.6K	$717.8K
YoY Change	-144.91%	-64.26%	11.51%
Pretax Income	-$3.917M	-$1.225M	-$740.4K
YoY Change	1941.59%	65.47%	-69.63%
Income Tax	$30.00K	$11.21K	$16.13K
% Of Pretax Income
Net Earnings	-$3.946M	-$1.236M	-$756.5K
YoY Change	1744.42%	63.42%	-68.96%
Net Earnings / Revenue	-12728667.74%	-74660.14%	-11.97%
Basic Earnings Per Share	-$0.08	-$0.02	-$0.02
Diluted Earnings Per Share	-$0.08	-$0.02	-$0.02
COMMON SHARES
Basic Shares Outstanding	52.31M shares	49.46M shares	48.33M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.90M	$15.80M	$11.80M
YoY Change	8.16%	33.9%	-16.9%
Cash & Equivalents	$15.94M	$15.79M	$11.78M
Short-Term Investments
Other Short-Term Assets	$200.0K	$700.0K	$700.0K
YoY Change	-50.0%	0.0%	-50.0%
Inventory
Prepaid Expenses
Receivables	$1.600M	$5.200M	$8.200M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.77M	$21.69M	$20.68M
YoY Change	-12.82%	4.88%	-9.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$429.5K	$460.1K	$625.5K
YoY Change	-22.34%	-26.45%	-37.45%
Goodwill	$2.348M	$2.348M	$2.348M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$74.59K	$85.91K	$150.5K
YoY Change	-42.93%	-42.91%	50.48%
Total Long-Term Assets	$2.853M	$2.894M	$3.124M
YoY Change	-5.93%	-7.36%	-8.1%
TOTAL ASSETS
Total Short-Term Assets	$17.77M	$21.69M	$20.68M
Total Long-Term Assets	$2.853M	$2.894M	$3.124M
Total Assets	$20.62M	$24.59M	$23.81M
YoY Change	-11.93%	3.27%	-9.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.159M	$2.993M	$2.063M
YoY Change	-37.23%	45.08%	-17.49%
Accrued Expenses	$2.600M	$2.100M	$3.100M
YoY Change	-18.75%	-32.26%	-8.82%
Deferred Revenue
YoY Change
Short-Term Debt		$1.168M	$0.00
YoY Change
Long-Term Debt Due	$1.000M	$1.000M	$454.5K
YoY Change	46.67%	120.0%
Total Short-Term Liabilities	$5.413M	$7.722M	$5.659M
YoY Change	-22.34%	36.46%	-4.08%
LONG-TERM LIABILITIES
Long-Term Debt	$974.4K	$1.218M	$1.984M
YoY Change	-44.77%	-38.61%
Other Long-Term Liabilities	$592.0K	$577.7K	$564.9K
YoY Change	2.13%	2.28%	-91.03%
Total Long-Term Liabilities	$1.566M	$1.796M	$2.548M
YoY Change	-33.17%	-29.54%	-59.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.413M	$7.722M	$5.659M
Total Long-Term Liabilities	$1.566M	$1.796M	$2.548M
Total Liabilities	$9.265M	$11.37M	$10.26M
YoY Change	-14.69%	10.76%	-15.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$205.9M	-$202.0M	-$197.1M
YoY Change	4.34%	2.45%
Common Stock	$217.5M	$215.4M	$209.7M
YoY Change	3.51%	2.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.35M	$13.22M	$13.55M
YoY Change
Total Liabilities & Shareholders Equity	$20.62M	$24.59M	$23.81M
YoY Change	-11.93%	3.27%	-9.48%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$3.946M	-$1.236M	-$756.5K
YoY Change	1744.42%	63.42%	-68.96%
Depreciation, Depletion And Amortization	$44.59K	$41.85K	$70.00K
YoY Change	-38.45%	-40.21%	-36.36%
Cash From Operating Activities	-$680.0K	-$490.0K	-$2.700M
YoY Change	-139.31%	-81.85%	107.69%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$40.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$10.00K	-$40.00K	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	840.0K	3.460M	-810.0K
YoY Change	-30.58%	-527.16%	-113.99%
NET CHANGE
Cash From Operating Activities	-680.0K	-490.0K	-2.700M
Cash From Investing Activities	-10.00K	-40.00K	0.000
Cash From Financing Activities	840.0K	3.460M	-810.0K
Net Change In Cash	150.0K	2.930M	-3.510M
YoY Change	-94.9%	-183.48%	-178.7%
FREE CASH FLOW
Cash From Operating Activities	-$680.0K	-$490.0K	-$2.700M
Capital Expenditures	-$10.00K	-$40.00K	$0.00
Free Cash Flow	-$670.0K	-$450.0K	-$2.700M
YoY Change	-138.73%	-83.33%	112.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001326190
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	52310913	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	PHARMATHENE, INC
	dei	Trading Symbol TradingSymbol	PIP
CY2013Q2	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2053522	USD
CY2012Q4	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2328877	USD
	pip	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate	0.12	pure
	pip	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate	0.12	pure
CY2012Q2	pip	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate	0.12	pure
CY2013Q2	pip	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate	0.12	pure
	pip	Supplemental Warrant Issued In Connection With Long Term Debt SupplementalWarrantIssuedInConnectionWithLongTermDebt		USD
	pip	Supplemental Warrant Issued In Connection With Long Term Debt SupplementalWarrantIssuedInConnectionWithLongTermDebt	69876	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2992549	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1697280	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-220274	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-217328	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	215392930	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	210495905	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	652589	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1060705	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	512041	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	324008	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11600000	shares
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11600000	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11700000	shares
CY2013Q2	us-gaap	Assets Assets	24586911	USD
CY2012Q4	us-gaap	Assets Assets	22741404	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	21692450	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	19795845	USD
CY2013Q2	us-gaap	Billed Contract Receivables BilledContractReceivables	1540060	USD
CY2012Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	2432641	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15789909	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12701517	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11776921	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11236771	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3088392	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	540150	USD
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51173919	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48352651	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51173919	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48352651	shares
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	5117	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	4835	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2012Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
	us-gaap	Contracts Revenue ContractsRevenue	10770538	USD
	us-gaap	Contracts Revenue ContractsRevenue	12466050	USD
CY2012Q2	us-gaap	Contracts Revenue ContractsRevenue	6316998	USD
CY2013Q2	us-gaap	Contracts Revenue ContractsRevenue	4295400	USD
	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	20000	USD
	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	1000000	USD
CY2012Q2	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	400000	USD
CY2013Q2	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense		USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	20949	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	166538	USD
CY2012Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	16133	USD
CY2013Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	11206	USD
CY2013Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2250001	USD
CY2012Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2500000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	94456	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	162358	USD
CY2012Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	76448	USD
CY2013Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41854	USD
CY2013Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1848566	USD
CY2012Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1295613	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20949	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	166538	USD
CY2013Q2	us-gaap	Deferred Revenue DeferredRevenue	508175	USD
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	1381755	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4080	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4434	USD
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1800000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M17D
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	66626	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4612525	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5728580	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2780099	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2332730	USD
CY2013Q2	us-gaap	Goodwill Goodwill	2348453	USD
CY2012Q4	us-gaap	Goodwill Goodwill	2348453	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3326808	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3269893	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-740410	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1225166	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20949	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	166538	USD
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16133	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11206	USD
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1217791	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1292796	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	617014	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-892581	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-979612	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-366136	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	408088	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-873580	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-495571	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-355878	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-248707	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-419811	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1765096	USD
	us-gaap	Interest Expense InterestExpense	199818	USD
	us-gaap	Interest Expense InterestExpense	114381	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	111353	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	100027	USD
	us-gaap	Interest Paid InterestPaid	129345	USD
	us-gaap	Interest Paid InterestPaid	73911	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2439	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7807	USD
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	4819	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1656	USD
CY2013Q2	us-gaap	Liabilities Liabilities	11366467	USD
CY2012Q4	us-gaap	Liabilities Liabilities	11067564	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24586911	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22741404	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7722385	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7488416	USD
CY2013Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	999996	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	749997	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	499998	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	750007	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	999996	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1704108	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	5777129	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-754345	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-220993	USD
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	717794	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3398040	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2389563	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70581	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	67400	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-234987	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1912379	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3347757	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3436431	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-756543	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1236372	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	256563	USD
	us-gaap	Operating Expenses OperatingExpenses	13343001	USD
	us-gaap	Operating Expenses OperatingExpenses	15514950	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	7775202	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2572463	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3048900	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	85907	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	113130	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1458204	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1481729	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2946	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6533	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-19902	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1262	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3350703	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3442964	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-776445	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1237634	USD
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	577725	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	579427	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4013	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	53434	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	519	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2110	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	70473	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	40470	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	216460	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70581	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	667850	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	547245	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3810403	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	38983	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	-249999	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2500000	USD
CY2013Q2	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	500000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities		USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-32960	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-162364	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit		USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities		USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	100000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	67400	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	460101	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	483976	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8636020	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9624012	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4918655	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3402545	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201957329	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-198609572	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	652589	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1060705	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	205000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	200948	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	185000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	145000	shares
CY2013Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	1168143	USD
CY2012Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1330507	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	13220444	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	11673840	USD
CY2013Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	3694631	USD
CY2012Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4114442	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-552953	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-167853	USD
CY2012Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	823809	USD
CY2013Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	352824	USD
	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Use of Estimates</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.  Our unaudited condensed consolidated financial statements include significant estimates for the value and the expected economic life of our intangible assets, the amount of our net operating losses available for income tax purposes, our share-based compensation, the value of our derivative financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in">  </p> <!--EndFragment--></div> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49058014	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48297919	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48325945	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49749167	shares

Files In Submission

Name	View Source	Status
0001144204-13-043745-index-headers.html	Edgar Link	pending
0001144204-13-043745-index.html	Edgar Link	pending
0001144204-13-043745.txt	Edgar Link	pending
0001144204-13-043745-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
pip-20130630.xml	Edgar Link	completed
pip-20130630.xsd	Edgar Link	pending
pip-20130630_cal.xml	Edgar Link	unprocessable
pip-20130630_def.xml	Edgar Link	unprocessable
pip-20130630_lab.xml	Edgar Link	unprocessable
pip-20130630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v349870_10q.htm	Edgar Link	pending
v349870_ex31-1.htm	Edgar Link	pending
v349870_ex31-2.htm	Edgar Link	pending
v349870_ex32-1.htm	Edgar Link	pending
v349870_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALT
Altimmune Inc Stock $alt

2013 Q3 Form 10-Q Financial Statement

#000114420413043745 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT Altimmune Inc Stock $alt

2013 Q3 Form 10-Q Financial Statement

#000114420413043745 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT
Altimmune Inc Stock $alt